NSX:SUG
NSX:SUGCommercial Services

3 ASX Dividend Stocks Yielding Up To 20.9%

As the Australian market navigates through fluctuating inflation data and potential interest rate decisions, investors are closely watching how these factors could influence various sectors on the ASX. In such an environment, dividend stocks can offer a reliable income stream, making them an appealing choice for those looking to capitalize on steady returns amidst broader market uncertainties.
ASX:LTR
ASX:LTRMetals and Mining

3 ASX Growth Stocks With High Insider Ownership And 73% Earnings Growth

As the Australian market navigates through fluctuating inflation data and potential interest rate adjustments, sectors such as IT are showing resilience with notable gains, while energy faces pressure from stabilizing oil prices. In this environment, growth companies with high insider ownership can be particularly appealing to investors seeking alignment between management and shareholder interests, especially when these firms demonstrate significant earnings growth.
ASX:FEX
ASX:FEXMetals and Mining

3 ASX Stocks Estimated To Be Trading Up To 46.1% Below Intrinsic Value

As the Australian market navigates a period of uncertainty with mixed signals from inflation data and potential rate hikes, investors are keenly observing sectors like IT and materials which have shown resilience amidst fluctuating conditions. In this environment, identifying undervalued stocks can be particularly rewarding, as these equities may offer significant upside potential once the broader economic landscape stabilizes.
ASX:RWL
ASX:RWLElectronic

Top 3 ASX Penny Stocks With Market Caps Over A$50M

As the Australian market shows resilience with a cooler-than-expected inflation read, investors are closely watching potential moves by the Reserve Bank of Australia. In such a climate, penny stocks can offer intriguing opportunities for those willing to explore beyond established names. Despite being an older term, penny stocks—often smaller or newer companies—remain relevant as they can provide affordability and growth potential when backed by strong financials.
ASX:GQG
ASX:GQGCapital Markets

GQG Partners (ASX:GQG) Valuation Check After CFO Transition To Charles Falck

GQG Partners (ASX:GQG) is back in focus after Charles Falck officially stepped into the chief financial officer role on 1 January 2026, following the retirement of long serving CFO Melodie Zakaluk. See our latest analysis for GQG Partners. The leadership change comes as the share price has shown positive momentum in recent months, with a 12.15% 90 day share price return but a 1 year total shareholder return decline of 2.25%, suggesting shorter term optimism alongside a more mixed longer term...
ASX:BSL
ASX:BSLMetals and Mining

BlueScope Steel (ASX:BSL) Valuation Check After Strong Recent Share Price Performance

BlueScope Steel: recent share performance in focus Recent trading in BlueScope Steel (ASX:BSL) has drawn attention after a strong run over the past 3 months, leaving investors weighing how the current A$29.87 share price lines up with fundamentals. See our latest analysis for BlueScope Steel. That recent 24.1% 7 day share price return and 37.97% 90 day share price return sit alongside a 58.6% 1 year total shareholder return. Together, these figures suggest strong momentum and a shift in how...
ASX:CSL
ASX:CSLBiotechs

Seqirus Spin-Off Pause and Plasma Push Could Be A Game Changer For CSL (ASX:CSL)

CSL has recently faced increased scrutiny after cutting its fiscal 2026 revenue growth outlook, pausing the planned Seqirus spin-off in response to weaker U.S. influenza vaccination demand, and committing A$1.50 billion over five years to expand its U.S. plasma-derived therapies manufacturing capacity. These moves highlight how CSL is recalibrating between a less certain vaccines backdrop and long-term investment in plasma therapies, sharpening questions about the balance between near-term...
ASX:TLX
ASX:TLXBiotechs

Should SEC Subpoena And FDA Letter Disclosures Require Action From Telix Pharmaceuticals (ASX:TLX) Investors?

In 2025–2026, Telix Pharmaceuticals became the focus of multiple securities class action lawsuits after disclosures of an SEC subpoena and an FDA Complete Response Letter concerning its prostate cancer diagnostics and therapeutics. The allegations center on whether Telix accurately described the progress of its pipeline and the robustness of its third-party manufacturing network, raising wider questions about disclosure practices in complex biotech supply chains. We’ll now examine how...
ASX:FFM
ASX:FFMMetals and Mining

Is It Too Late To Consider FireFly Metals (ASX:FFM) After A 123% Share Price Jump?

Wondering if FireFly Metals at A$2.03 is starting to look priced for perfection, or if the market is still underestimating it? This article walks through the key numbers so you can judge the value story for yourself. The share price has seen a 123.1% return over the last year, alongside a 9.7% gain over the past 30 days and a 2.9% decline in the last week. This hints at both interest in the stock and some short term volatility in how risk is being priced. Recent attention around FireFly...
ASX:4DX
ASX:4DXHealthcare Services

Assessing 4DMedical’s Valuation After Julian Sutton’s CFO Appointment And CT:VQ Commercial Progress

Why Julian Sutton’s promotion matters for 4DMedical shareholders The recent 18% jump in 4DMedical (ASX:4DX) followed the appointment of long-time board member and early investor Julian Sutton as Chief Financial Officer and Executive Director on January 2, 2026. This move comes as the company shifts focus toward commercial growth, with its CT:VQ lung imaging software already FDA cleared, deployed at leading U.S. academic medical centres, and supported by a global distribution agreement with...
ASX:CXL
ASX:CXLChemicals

A Look At Calix’s Valuation After New Three Year US Agriculture Contract And Share Price Surge

Calix (ASX:CXL) has drawn fresh attention after securing a three year supply contract with a major US agricultural company. The contract is expected to contribute up to A$10 million in revenue each year. See our latest analysis for Calix. The contract news arrived after a sharp move in the share price, with a 30 day share price return of 122.61% and a 90 day share price return of 224.05%. However, the 3 year total shareholder return of a 72.94% decline shows that longer term holders have had...
ASX:JHX
ASX:JHXBasic Materials

A Look At James Hardie Industries (ASX:JHX) Valuation After Renewed Confidence In Margins And Construction Demand

James Hardie Industries (ASX:JHX) has drawn fresh attention after a multi month rally that brought the stock close to its 52 week highs, as investors focus on margin discipline and resilient North American construction demand. See our latest analysis for James Hardie Industries. At A$31.35, the stock has a 1 month share price return of 5.48%, even though the 90 day share price return is a 5.69% decline and the 1 year total shareholder return is a 37.43% loss. Recent momentum is improving off...
ASX:ANZ
ASX:ANZBanks

Investor Shift Toward ANZ’s Dividend and Digital Story Might Change The Case For Investing In ANZ Group Holdings (ASX:ANZ)

ANZ Group Holdings has recently drawn fresh investor attention as a major Australia–New Zealand bank, with its long history of dividend payments, strong capital position and ongoing digital transformation underpinning confidence in the group’s ability to generate income for shareholders. Recent commentary highlights that investors increasingly view ANZ as a way to diversify beyond US markets while gaining exposure to Australia–New Zealand banking, underpinned by stable asset quality,...
ASX:QBE
ASX:QBEInsurance

Did QBE’s $400m Catastrophe Bond Just Reframe QBE Insurance Group's (ASX:QBE) Risk Playbook?

QBE Insurance Group recently completed a $400 million catastrophe bond through its Bridge Street Re Ltd. program, securing three years of collateralized reinsurance protection focused on earthquake risk in Australasia and the US. This move broadens QBE’s access to insurance-linked securities and reinforces its capital management toolkit at a time of slowing premium growth. We’ll now explore how QBE’s expanded catastrophe bond protection shapes its investment narrative, particularly its...